KIT Gene Gastrointestinal Stromal Tumor clinical trials
10 active Gastrointestinal Stromal Tumor trials that test for KIT Gene in their eligibility criteria. Describe your situation to see which ones look like a fit.
- A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
- A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
- KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Imatinib TDM in GIST
- A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
← All Gastrointestinal Stromal Tumor trials
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.